To investigate a potential application of our newly characterized salicylate- and diflunisal-mediated inhibition of CBP/p300 activity, we tested the effects of various doses of salicylate and diflunisal on two AML1-ETO expressing cancer cell lines (human Kasumi-1 cells and a mouse AE9a-driven AML cell line that we generated). The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.